Oral Anticoagulation and the Novel Oral Anticoagulants (NOACs):Where Are We at Midterm?

Academic Content

Program Overview

Faculty Presentations

Introduction Deepak L. Bhatt Elaine Hylek

Video Roundtable

Current Activity

Elaine Hylek, MD, MPH, Boston University School of Medicine, Boston, Massachusetts

NOACs in Clinical Care NOACS Prevention Data NOACS: Major Bleeding Meta-Analysis ESC 2012 Guidelines Update Garfield Registry Prophylaxis vs Anticoagulation Clinical Trial: Major Bleeding Benefit and Risk Bleeding Risk Score Consensus Statements CHA2DS2-VASc Bleeding Risk Score Circulation Article Patient Age vs TTR NOACs vs Warfarin NOACS & Renal Dysfunction EHRA NOACs Practical Guide Procedural Management NOACs Bleeding Management Life-threatening Hemorrhage CAT Scans of Cerebral Hemorrhage Intracerebral Hemorrhage: Limited Data Kcentra: FDA approval Safety: Meta-analysis Anticoagulation Antidotes Dose Differences: AFib vs VTE NOACS in Clinical Practice Continuing role for warfarin?

Return to:

The American Journal of Medicine

« Prev

Next »
Click Figure to Enlarge

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

The American Journal of Medicine

Print This Page

EHRA Practical Guide on the Use of NOACs

The European Heart Rhythm Association (EHRA) has published a practical guide for the use of NOACs in patients with AFib (Figure 18).[14] Physicians who see patients with AFib or heart failure should download this document and have it on their desktop; it is very well written and it gives us practical guidelines on how to use these novel oral agents in practice.

Hylek EM. Am J Med 2014; 00.

References

[14]

Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651.